Intellia Therapeutics’ (NTLA) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report sent to investors on Friday morning,Benzinga reports. Chardan Capital currently has a $26.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the stock. Wolfe Research reissued a “peer perform” rating on shares of Intellia Therapeutics in a research report on Wednesday, November 12th. Wells Fargo & Company lowered their target price on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. JPMorgan Chase & Co. restated an “underweight” rating and issued a $5.00 price target (down from $12.00) on shares of Intellia Therapeutics in a research report on Friday, November 7th. Citizens Jmp decreased their price objective on Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Finally, KeyCorp set a $25.00 price objective on Intellia Therapeutics in a research report on Wednesday, January 28th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.90.

Intellia Therapeutics Stock Down 3.5%

NASDAQ NTLA opened at $13.78 on Friday. The company has a 50-day moving average price of $11.89 and a 200-day moving average price of $13.05. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25. The firm has a market capitalization of $1.63 billion, a P/E ratio of -3.60 and a beta of 2.09.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. During the same quarter last year, the firm posted ($1.27) earnings per share. The firm’s revenue was up 78.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the transaction, the chief executive officer owned 1,013,339 shares in the company, valued at $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the sale, the executive vice president directly owned 98,533 shares in the company, valued at $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 53,051 shares of company stock valued at $488,600. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Contrarius Group Holdings Ltd increased its position in Intellia Therapeutics by 279.4% during the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after acquiring an additional 4,337,428 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Intellia Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after purchasing an additional 2,288,146 shares during the period. Vanguard Group Inc. grew its holdings in Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after purchasing an additional 1,965,181 shares during the last quarter. State Street Corp raised its position in Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock worth $57,705,000 after purchasing an additional 1,447,967 shares during the period. Finally, Jupiter Asset Management Ltd. bought a new stake in Intellia Therapeutics in the third quarter worth about $23,519,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations: Intellia reported a smaller-than-expected loss (‑$0.83 vs. consensus ‑$0.99) and revenue of $23.0M (well above estimates), which investors view as proof of commercial progress and operational execution. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Positive Sentiment: Pipeline and regulatory progress: FDA lifted the clinical hold on MAGNITUDE‑2 (nex‑z) and management outlined 2026 launch plans for lonvo‑z (HAE) with mid‑2026 Phase 3 readout expectations and a potential BLA in H2 2026 — milestones that materially de‑risk commercial timelines if achieved. Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Strong cash runway: Intellia ended 2025 with roughly $605M in cash, cash equivalents and marketable securities — a balance that supports continued clinical development and commercial preparation into the near‑term. Intellia Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” and set a $26 price target, signaling notable upside from current levels and providing dealer/retail validation for the bull case. Benzinga
• Neutral Sentiment: Broker estimates: Brookline Capital published a slate of near‑term quarterly EPS forecasts (all negative) but raised long‑range FY2028/FY2029 EPS projections, reflecting high uncertainty today but improved long‑term expectations if pipeline succeeds. MarketBeat Q4 coverage / analyst notes
• Neutral Sentiment: Earnings call detail: Management emphasized commercial readiness for lonvo‑z and clinical plans for nex‑z; transcripts and call highlights are available for deeper review. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Profitability and consensus outlook remain weak: the company still posts large negative margins and the consensus full‑year EPS forecast is deeply negative, keeping NTLA a high‑volatility, binary biotech bet until clinical/commercial milestones are met. MarketBeat: Q4 results and metrics
• Negative Sentiment: Market reaction: despite the positive operational news, the shares are trading lower today — likely reflecting profit‑taking, macro/sector pressure on biotech, and investor caution about execution risk and near‑term losses.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.